{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:48Z","timestamp":1786119288703,"version":"build-2736575974"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/cji.0b013e3181b8bdb9","type":"journal-article","created":{"date-parts":[[2009,12,17]],"date-time":"2009-12-17T10:24:55Z","timestamp":1261045495000},"page":"106-114","source":"Crossref","is-referenced-by-count":33,"title":["Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-\u03b1 Treatment in Patients With Malignant Melanoma"],"prefix":"10.1097","volume":"33","author":[{"given":"Sarah","family":"Heinze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"R\u00f6tzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Volkenandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Tilgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruthild","family":"Linse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Boettjer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"Spieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert H.","family":"Brockmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hinzpeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210227","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5\u2009mm without clinically detectable node metastases. French Cooperative Group on Melanoma","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet"},{"key":"R2-12-20210227","first-page":"7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Psychol"},{"key":"R3-12-20210227","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group","volume":"16","author":"Pehamberger","year":"1998","journal-title":"J Clin Oncol"},{"key":"R4-12-20210227","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon Alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"key":"R5-12-20210227","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the american joint committee on cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R6-12-20210227","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"R7-12-20210227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF03259051","article-title":"Major therapeutic uses of interferons","volume":"3","author":"Cirelli","year":"1995","journal-title":"Clin Immunother"},{"key":"R8-12-20210227","first-page":"436","article-title":"Interferon alpha 2a","volume":"57","author":"Williams","year":"1997","journal-title":"Br J Hosp Med"},{"key":"R9-12-20210227","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in cancer patients: a review","volume":"4","author":"Quesada","year":"1986","journal-title":"J Clin Oncol"},{"key":"R10-12-20210227","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hep.510260720","article-title":"Side effects of alpha interferon in hepatitis C","volume":"26","author":"Dusheiko","year":"1997","journal-title":"Hepatology"},{"key":"R11-12-20210227","first-page":"353","article-title":"Suicidal impulses in patients with chronic viral hepatitis C treated by alpha interferon","volume":"22","author":"Rifflet","year":"1998","journal-title":"Gastroen Clin Biol"},{"key":"R12-12-20210227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1023\/A:1022449613907","article-title":"Neuropsychiatric side effects of interferon-alfa therapy","volume":"25","author":"Van Gool","year":"2003","journal-title":"Pharm World Sci"},{"key":"R13-12-20210227","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1176\/jnp.9.2.273","article-title":"Manic episodes in two patients treated with interferon-alpha","volume":"9","author":"Strite","year":"1997","journal-title":"J Neuropsych Clin N"},{"key":"R14-12-20210227","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1055\/s-2003-42188","article-title":"Interferon-alpha-assoziierte psychische nebenwirkungen","volume":"71","author":"Schaefer","year":"2003","journal-title":"Fortschr Neurol Psychiat"},{"key":"R15-12-20210227","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0278-5846(01)00324-4","article-title":"Interferon alpha (IFNalpha) and psychiatric syndromes: a review","volume":"26","author":"Schaefer","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R16-12-20210227","first-page":"39","article-title":"Mood and cognitive side effects of interferon-alpha therapy","volume":"25","author":"Valentine","year":"1998","journal-title":"Semin Oncol"},{"key":"R17-12-20210227","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1461145702003103","article-title":"The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans","volume":"5","author":"Wichers","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"R18-12-20210227","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","article-title":"Clinical toxicity of the interferons","volume":"10","author":"Vial","year":"1994","journal-title":"Drug Saf"},{"key":"R19-12-20210227","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJM199904293401716","article-title":"Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state","volume":"340","author":"Capuron","year":"1999","journal-title":"N Engl J Med"},{"key":"R20-12-20210227","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of Interferon alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"R21-12-20210227","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbi.2003.11.004","article-title":"Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and\/or interferon-alpha cancer therapy","volume":"18","author":"Capuron","year":"2004","journal-title":"Brain Behav Immun"},{"key":"R22-12-20210227","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archinte.1987.00370090055011","article-title":"Psychiatric complications of long-term interferon-alpha therapy","volume":"147","author":"Renault","year":"1987","journal-title":"Arch Intern Med"},{"key":"R23-12-20210227","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/jhep.2003.50031","article-title":"Adherence and mental side effects during hepatitis c treatment with interferon alfa and ribavirin in psychiatric risk groups","volume":"37","author":"Schaefer","year":"2003","journal-title":"Hepatology"},{"key":"R24-12-20210227","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00001813-199212000-00002","article-title":"Neurotoxicity of interferon-alpha","volume":"3","author":"Merimsky","year":"1992","journal-title":"Anticancer Drugs"},{"key":"R25-12-20210227","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"R26-12-20210227","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000066239","article-title":"On the validity of the beck depression inventory a review","volume":"31","author":"Richter","year":"1998","journal-title":"Psychopathology"},{"key":"R27-12-20210227","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.2044-8260.1977.tb00241.x","article-title":"Factorial invariance across gender for the primary symptom dimensions of the SCL-90","volume":"16","author":"Derogatis","year":"1977","journal-title":"Br J Soc Clin Psychol"},{"key":"R28-12-20210227","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.psy.45.2.176","article-title":"Depression during treatment with interferon alpha","volume":"45","author":"Schaefer","year":"2004","journal-title":"Psychosomatics"},{"key":"R29-12-20210227","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0889-1591(02)00078-8","article-title":"Cytokines and depression: the need for a new paradigm","volume":"17","author":"Capuron","year":"2003","journal-title":"Brain Behav Immun"},{"key":"R30-12-20210227","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.21791","article-title":"Hepatitis C treatment in \u201cdifficult-to-treat\u201d psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects","volume":"46","author":"Schaefer","year":"2007","journal-title":"Hepatology"},{"key":"R31-12-20210227","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1200\/JCO.2000.18.11.2316","article-title":"Psychiatric side effects of interferon therapy: prevalence proposed mechanisms and future directions","volume":"18","author":"Trask","year":"2000","journal-title":"J Clin Oncol"},{"key":"R32-12-20210227","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2131\/jts.21.93","article-title":"Psychiatric side effects of interferon","volume":"21","author":"Yokoyama","year":"1996","journal-title":"J Toxicol Sci"},{"key":"R33-12-20210227","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1200\/JCO.2002.03.052","article-title":"Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy","volume":"20","author":"Kirkwood","year":"2002","journal-title":"J Clin Oncol"},{"key":"R34-12-20210227","first-page":"16","article-title":"Efficacy, safety and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma","volume":"24","author":"Kirkwood","year":"1997","journal-title":"Semin Oncol"},{"key":"R35-12-20210227","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N Engl J Med"},{"key":"R36-12-20210227","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioural effects of interferon alpha in cancer patients; phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R37-12-20210227","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/(SICI)1097-0142(19980801)83:3<482::AID-CNCR17>3.0.CO;2-S","article-title":"Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial","volume":"83","author":"Caraceni","year":"1998","journal-title":"Cancer"},{"key":"R38-12-20210227","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa","volume":"321","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"key":"R39-12-20210227","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(01)06068-8","article-title":"Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional lymph node metastases from cutaneous melanoma: a randomised trial","volume":"358","author":"Cascinelli","year":"2001","journal-title":"Lancet"},{"key":"R40-12-20210227","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(94)90030-2","article-title":"Results of adjuvant interferon study in WHO melanoma programme","volume":"343","author":"Cascinelli","year":"1994","journal-title":"Lancet"},{"key":"R41-12-20210227","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/pon.770","article-title":"Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon","volume":"13","author":"Trask","year":"2004","journal-title":"Psycho-Oncology"},{"key":"R42-12-20210227","article-title":"The Handbook of Psychological Assessment. 2nd ed","author":"Groth-Marnat","year":"1990"},{"key":"R43-12-20210227","article-title":"On Death and Dying","author":"K\u00fcbler-Ross","year":"1969"},{"key":"R44-12-20210227","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-2002-24953","article-title":"Das \u201cZufriedenheitsparadox\u201d in der Lebensqualit\u00e4tsforschung","volume":"52","author":"Herschbach","year":"2002","journal-title":"Psychother Psych Med"},{"key":"R45-12-20210227","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-2003-38005","article-title":"Traumatische und psychosoziale Belastungen bei Patienten mit akuter Tumorerkrankung","volume":"53","author":"Flatten","year":"2003","journal-title":"Psychother Psych Med"},{"key":"R46-12-20210227","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1200\/JCO.2001.19.11.2844","article-title":"Psychosocial characteristics of individuals wiith non-stage melanoma","volume":"19","author":"Trask","year":"2001","journal-title":"J Clin Oncol"},{"key":"R47-12-20210227","first-page":"48","article-title":"Fatigue: definitions, mechanisms, and paradigms for study","volume":"25","author":"Dalakas","year":"1998","journal-title":"Semin Oncol"},{"key":"R48-12-20210227","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/15622970310029904","article-title":"Hepatitis C, alfa interferon, anxiety and depression disorders: a prospective study of 71 patients","volume":"4","author":"Gohier","year":"2003","journal-title":"World J Biol Psychiatry"},{"key":"R49-12-20210227","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000067682","article-title":"Assessment of depression in patients with chronic hepatitis: effect of interferon treatment","volume":"20","author":"Koskinas","year":"2002","journal-title":"Dig Diss"},{"key":"R50-12-20210227","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1176\/appi.psy.43.5.378","article-title":"Emotional distress during interferon alpha-2B and ribavirin treatment of chronic hepatitis C","volume":"43","author":"Fontana","year":"2002","journal-title":"Psychosomatics"},{"key":"R51-12-20210227","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4088\/JCP.v64n0614","article-title":"Psychiatric symptoms in patients with chronic hepatitis C recieving interferon alpha-2B therapy.","volume":"64","author":"Kraus","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R52-12-20210227","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-0327(02)00264-1","article-title":"Depression induced by treatment with interferon alfa in patients affected by hepatitis C virus","volume":"72","author":"Bonaccorso","year":"2002","journal-title":"J Affect Disord"},{"key":"R53-12-20210227","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1176\/ajp.156.7.1120","article-title":"Depression from interferon therapy in patients with hepatitis C","volume":"156","author":"Miyaoka","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R54-12-20210227","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-200202000-00014","article-title":"Increased depressive ratings in patients with hepatitis c receiving interferon-[alpha]\u2013based immunotherapy are related to interferon-[alpha]\u2013induced changes in the serotonergic system","volume":"22","author":"Bonaccorso","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"R55-12-20210227","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.cad.0000132230.51759.8d","article-title":"Pegylated interferon-alpha2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations","volume":"15","author":"Van Gool","year":"2004","journal-title":"Anticancer Drugs"},{"key":"R56-12-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0165-1781(03)00113-6","article-title":"Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients","volume":"119","author":"Van Gool","year":"2003","journal-title":"Psychiatry Res"},{"key":"R57-12-20210227","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/sj.mp.4000995","article-title":"Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy","volume":"7","author":"Capuron","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R58-12-20210227","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pnpbp.2004.10.012","article-title":"Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients","volume":"29","author":"Bannink","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R59-12-20210227","first-page":"11","article-title":"The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha induced depression","volume":"29","author":"Wichers","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"R60-12-20210227","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.mp.4001600","article-title":"IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity","volume":"10","author":"Wichers","year":"2005","journal-title":"Mol Psychiatry"},{"key":"R61-12-20210227","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jhep.2005.01.024","article-title":"Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression","volume":"42","author":"Cai","year":"2005","journal-title":"J Hepatol"},{"key":"R62-12-20210227","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.biopsych.2007.05.026","article-title":"Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression","volume":"62","author":"Felger","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R63-12-20210227","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-1781(01)00315-8","article-title":"Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokin network and an increase in depressive and anxiety symptoms","volume":"105","author":"Bonaccorso","year":"2001","journal-title":"Psychiatry Res"},{"key":"R64-12-20210227","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.cji.0000211346.19330.c9","article-title":"Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma","volume":"30","author":"Friebe","year":"2007","journal-title":"J Immunother"},{"key":"R65-12-20210227","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbi.2004.02.002","article-title":"Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha","volume":"18","author":"Schaefer","year":"2004","journal-title":"Brain Behav Immun"},{"issue":"3","key":"R66-12-20210227","first-page":"203","article-title":"Neurotransmitter changes by interferon-alpha and therapeutic implications","volume":"36","author":"Schaefer","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"R67-12-20210227","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.psy.41.5.439","article-title":"Prophylactic treatment of depression induced by interferon-alpha","volume":"41","author":"Hauser","year":"2000","journal-title":"Psychosomatics"},{"key":"R68-12-20210227","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0b013e3282f702bf","article-title":"Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting","volume":"18","author":"Garbe","year":"2008","journal-title":"Melanoma Res"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CJI.0b013e3181b8bdb9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:11:36Z","timestamp":1786039896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002371-201001000-00012"}},"subtitle":["Results From the Multicenter DeCOG Trial"],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e3181b8bdb9","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}